Any current/future new fundraising through debt or equity?

As of March 31, 2023, for the Tarapur expansion, NGL Fine Chem Limited had spent about ₹31 Crores with zero debt taken. The company is currently funding its expansion plans entirely through internal accruals, avoiding any borrowings. Due to the current market environment and demand uncertainties, the company is deliberately slowing down expansion and capital expenditure. They prefer to avoid debt financing to prevent increased interest and depreciation burdens in the absence of strong demand. Overall, no current or immediate future plans for raising funds through debt or equity have been indic

Any current/future capex/capital investment/strategic investment?

NGL Fine Chem has a planned Tarapur expansion initially budgeted at Rs. 100 Crores, now estimated between Rs. 140-150 Crores due to inflation. As of March 31, 2023, Rs. 31 Crores (including advances) has been spent on this expansion with no debt taken for it. The company is proceeding cautiously with the expansion, opting for a slower pace to fund the project entirely through internal accruals and avoid debt, awaiting clear demand recovery. Equipment selection is done but final orders and negotiations will proceed only upon demand improvement. The expected capacity post-expansion, based on ind

Future growth expectations in sales/revenue/volumes?

The company anticipates accommodating growth up to 30-35% through existing plants and increased outsourcing without immediate capacity expansion. New products and capacity utilization improvements support steady revenue growth. Expansion plans, including the Tarapur facility by FY2026, aim to raise revenues to approximately ₹650 Crores. Market recovery and demand normalization are expected within 3-6 months, supporting growth beyond FY2023. The company targets volume growth to offset price declines (which range 15-20%) to maintain topline. New products launched contribute to revenue with marke

Future growth expectations in earnings/operating earnings/profits/EPS?

Post-expansion, with a ₹150 Crores investment, the company expects turnover between ₹350 to ₹400 Crores (Page 16). The company aims for EBITDA margins in the range of 17% to 23%; achieving 25%+ is considered difficult (Page 12). Volume growth is expected as the company launches new products and increases utilization, supported by multi-product existing facilities (Pages 7-8). Slower expansion is planned to fund growth through internal accruals, avoiding debt amid rising interest costs (Pages 9, 15-16). The company sees potential to accommodate 20-25% growth in existing plants, plus 10% via out

Current/ Expected Orderbook/ Pending Orders?

The document does not explicitly mention the current or expected order book or pending orders. There is an indication of cautious customer behavior and inventory destocking impacting demand. Demand is expected to gradually recover as inventory destocking approaches its tail end. Some challenges remain due to economic conditions in certain countries and ongoing uncertainties. New products have been validated and commercial supply is starting, potentially supporting future orders. The company is prepared to scale capacity using existing facilities and outsourcing when demand recovers. Capex and

NGL Fine Chem LtdQ4 FY23Pharmaceuticals & Biotechnology

NGL Fine Chem Ltd Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,612.8P/E: 32.0Market Cap: ₹1.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4

The company anticipates accommodating growth up to 30-35% through existing plants and increased outsourcing without immediate capacity expansion.
New products and capacity utilization improvements support steady revenue growth.
Expansion plans, including the Tarapur facility by FY2026, aim to raise revenues to approximately ₹650 Crores.
Market recovery and demand normalization are expected within 3-6 months, supporting growth beyond FY2023.
The company targets volume growth to offset price declines (which range 15-20%) to maintain topline.
New products launched contribute to revenue with market sizes of ₹30-60 Crores each, expanding the product portfolio.
Export market expansion plans, including Europe, present significant growth opportunities over the next 5-6 years.
Demand recovery timing influences capital expenditure plans and pace of capacity expansion.

Margin guidance

Category 3

Post-expansion, with a ₹150 Crores investment, the company expects turnover between ₹350 to ₹400 Crores (Page 16).
The company aims for EBITDA margins in the range of 17% to 23%; achieving 25%+ is considered difficult (Page 12).
Volume growth is expected as the company launches new products and increases utilization, supported by multi-product existing facilities (Pages 7-8).
Slower expansion is planned to fund growth through internal accruals, avoiding debt amid rising interest costs (Pages 9, 15-16).
The company sees potential to accommodate 20-25% growth in existing plants, plus 10% via outsourcing (Page 9).
Half-yearly earnings calls will replace quarterly, suggesting steady but not rapid changes in operating performance (Page 16).
Market expansion into Europe and companion animal segments offers further growth opportunities over 5-6 years (Page 12).

See what NGL Fine Chem Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

As of March 31, 2023, for the Tarapur expansion, NGL Fine Chem Limited had spent about ₹31 Crores with zero debt taken.
The company is currently funding its expansion plans entirely through internal accruals, avoiding any borrowings.
Due to the current market environment and demand uncertainties, the company is deliberately slowing down expansion and capital expenditure.
They prefer to avoid debt financing to prevent increased interest and depreciation burdens in the absence of strong demand.
Overall, no current or immediate future plans for raising funds through debt or equity have been indicated; expansion will be funded internally once demand recovery is clear.

Order book

The document does not explicitly mention the current or expected order book or pending orders.
There is an indication of cautious customer behavior and inventory destocking impacting demand.
Demand is expected to gradually recover as inventory destocking approaches its tail end.
Some challenges remain due to economic conditions in certain countries and ongoing uncertainties.
New products have been validated and commercial supply is starting, potentially supporting future orders.
The company is prepared to scale capacity using existing facilities and outsourcing when demand recovers.
Capex and capacity expansion plans are on hold until clear demand recovery signals are observed.
Overall, while demand is subdued currently, there is optimism for order inflow recovery in the near future.

See what NGL Fine Chem Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

NGL Fine Chem has a planned Tarapur expansion initially budgeted at Rs. 100 Crores, now estimated between Rs. 140-150 Crores due to inflation.
As of March 31, 2023, Rs. 31 Crores (including advances) has been spent on this expansion with no debt taken for it.
The company is proceeding cautiously with the expansion, opting for a slower pace to fund the project entirely through internal accruals and avoid debt, awaiting clear demand recovery.
Equipment selection is done but final orders and negotiations will proceed only upon demand improvement.
The expected capacity post-expansion, based on industry capital turnover ratio of 2 to 2.5, is an estimated Rs. 350 to 400 Crores turnover from Rs. 150 Crores investment.
The timeline for commissioning the expansion is uncertain ("wait and watch"), with an original target of March 2024 now delayed by 6-12 months.
Strategic focus remains on managing resources optimally without increasing leverage while being ready to accelerate expansion once demand signals improve.

Track NGL Fine Chem Ltd — get its next earnings analysis in your feed

How does NGL Fine Chem Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisNGL Fine Chem Ltd

Rev 4Mar 3

See where NGL Fine Chem Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does NGL Fine Chem Ltd rank in Pharmaceuticals & Biotechnology?

Compare NGL Fine Chem Ltd against every Pharmaceuticals & Biotechnology company (Q4 FY23) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What NGL Fine Chem Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →